CBIO CRESCENT BIOPHARMA INC.

Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York on Thursday, February 12, 2026 at 11:30 a.m. ET.

A live webcast of the presentation will be available in the Investors section of the Company's website at , and a replay will be accessible for 90 days following the event.

About Crescent Biopharma

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit and follow the Company on and .

Contact:

Amy Reilly

Chief Communications Officer



617-465-0586



EN
05/02/2026

Underlying

CBIOCRESCENT BIOPHARMA INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CRESCENT BIOPHARMA INC.

Geoffrey Von Der Ahe ... (+2)
  • Geoffrey Von Der Ahe
  • Robert Driscoll
CBIO CRESCENT BIOPHARMA INC.
02/26/26 February 26, 2026 1 EN
 PRESS RELEASE
Free
CBIO CRESCENT BIOPHA...

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial...

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple ADCs ASCEND Phase 1/2 global clinical trial underway to evaluate CR-001 in advanced solid tumors with three additional clinical trials across the portfolio expected to initiate in 2026 Completed $185 million private placement, supporting several key clinical data readouts beginning in Q1 2027 and providing expected cash run...

February 26, 2026 1 EN
 PRESS RELEASE
Free
CBIO CRESCENT BIOPHA...

Crescent Biopharma to Present at March Investor Conferences

Crescent Biopharma to Present at March Investor Conferences WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in March: TD Cowen 46th Annual Health Care Conference, fireside chat on Monday, March 2, 2026 at 3:50 p.m. ET in Boston.Leerink Partners 2026 Global Healthcare Conference, fireside chat on Wednesday, March 11, 2026 at 8:40 a....

February 23, 2026 1 EN
 PRESS RELEASE
Free
CBIO CRESCENT BIOPHA...

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 24,600 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incen...

February 19, 2026 1 EN
 PRESS RELEASE
Free
CBIO CRESCENT BIOPHA...

Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 C...

Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and gynecological cancers in first-line and previously treated patients Company anticipates reporting proof-of-concept data in the first quarter of 2027 ASCEND is the first of four clinical trials across the portfolio expected to initiate in 2026 WALTHAM, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- (“Crescent” or the “Company...

February 18, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch